Glycated Hemoglobin Variability Is Associated With Adverse Outcomes in Patients With Heart Failure Irrespective of Diabetic Status

Author:

Xu Xin12ORCID,Ren Qing‐Wen12ORCID,Chandramouli Chanchal34ORCID,Ng Ming‐Yen56ORCID,Tsang Christopher Tze‐Wei2ORCID,Tse Yi‐Kei2,Li Xin‐Li7ORCID,Liu Ming‐Ya1,Wu Mei‐Zhen12ORCID,Huang Jia‐Yi12,Cheang Iok‐Fai7ORCID,Yang Jie‐Fu8ORCID,Wang Fang8ORCID,Lam Carolyn S.P.349ORCID,Yiu Kai‐Hang12ORCID

Affiliation:

1. Cardiology Division, Department of Medicine The University of Hong Kong–Shen Zhen Hospital Shenzhen China

2. Cardiology Division, Department of Medicine The University of Hong Kong, Queen Mary Hospital Hong Kong China

3. Department of Cardiology National Heart Center Singapore Singapore

4. Duke‐NUS Medical School Singapore

5. Department of Diagnostic Radiology, School of Clinical Medicine The University of Hong Kong, Li Ka Shing Faculty of Medicine Hong Kong China

6. Department of Medical Imaging The University of Hong Kong‐Shen Zhen Hospital Shenzhen China

7. Department of Cardiology The First Affiliated Hospital of Nanjing Medical University Nanjing China

8. Department of Cardiology, Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing China

9. Baim Institute for Clinical Research Boston MA USA

Abstract

Background The effect of glycated hemoglobin (HbA 1c ) variability on adverse outcomes in patients with heart failure (HF) is unclear. We aim to investigate the predictive value of HbA 1c variability on the risks of all‐cause death and HF rehospitalization in patients with HF irrespective of their diabetic status. Methods and Results Using a previously validated territory‐wide clinical data registry, HbA 1c variability was assessed by average successive variability (ASV) or SD of all HbA 1c measurements after HF diagnosis. Multivariable Cox proportional hazards models were used to estimate the adjusted hazard ratio (HR) and its corresponding 95% CI. A total of 65 950 patients with HF were included in the study. Over a median follow‐up of 6.7 (interquartile range, 4.0–10.6) years, 34 508 patients died and 52 446 required HF rehospitalization. Every unit increment of variability in HbA 1c was significantly associated with higher HF rehospitalization (HR ASV, 1.20 [95% CI, 1.18–1.23]) and all‐cause death (HR ASV, 1.50 [95% CI, 1.47–1.53]). Diabetes significantly modified the association between HbA 1c variability and outcomes ( P interaction <0.001). HbA 1c variability in patients with HF without diabetes conferred a higher risk of rehospitalization (HR ASV, 1.92 [95% CI, 1.70–2.17] versus HR ASV, 1.19 [95% CI, 1.17–1.21]), and all‐cause death (HR ASV, 3.90 [95% CI, 3.31–4.61] versus HR ASV, 1.47 [95% CI, 1.43–1.50] compared with patients with diabetes). Conclusions HbA 1c variability is significantly associated with greater risk of rehospitalization and all‐cause death in patients with HF, irrespective of their diabetic status. These observations were more pronounced in patients with HF without diabetes.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3